How to Cite
Abstract
There was conducted a study of edematous-infiltrative form of breast cancer in comparison with other forms of locally advanced breast cancer in various molecular-biological parameters. It was provided an evaluation of expression of receptors of steroid hormones, mutational status of HER2/neu gene, mutation status of ALK gene (a number of copies of a gene, translocation of EML4-ALK, point mutations in exons 22-25). There were studied mutational changes of genes of signaling pathway PIK3-AKT-mTOR (point mutations in exons 9 and 2° of PIK3CA gene and 4 in exon of AKT gene), mutations in exons 5-8 of p53 gene. It was found that in edematous breast cancer significantly more frequently there were met tumors with negative receptor status (p = 0.006) and a positive HER2/neu status (p<O,OOl). In 5% of patients with edematous-infiltrative breast cancer there was detected translocation of EML4-ALK (p = 0.045), while it was not found a single case of ALK gene amplification. In the analysis of PIK3CA gene it was revealed that significantly frequently mutations localized in exon 9 (p =0.038). There were no statistically substantial differences in the number of point mutations of p53 gene between a group of edematous-infiltrative breast cancer and a control group.References
Allred D., Harvey J., Berardo M. et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis // Mod. Pathol. -1998. - Vol. 11 (2). - P. 155-168.
Barbareschi M., Buttitta F., Felicioni L. et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas // Clin. Cancer Res. - 2007. - Vol. 13. (20). - P. 6064-6069.
Bertucci F., Finetti P., Birnbaum D. et al. Gene Expression Profiling of Inflammatory Breast Cancer // Cancer Res. - 2010. - Vol. 116 (11). - Р. 2783-2793.
Dirix L., Vermeulen P. Inflammatory HER2-positive breast cancer // Lancet Oncology. - 2012. - Vol. 13 (4). - P. 324-326.
Dong H., Liu G., Hou Y et al. Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro // J. Cancer Res Clin. Oncol. - 2007. - Vol. 133 (2). - P. 83-92.
Golen K., Wu Z., Qiao X. et al. RhoCGTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype // Cancer Res. - 2000. - Vol. 60 (20). - Р. 5832-5838.
Gonzalez-Angulo A., Sneige N., Buzdar A. et al. p53 expression as a prognostic marker in inflammatory breast cancer // Clin. Cancer Res. - 2004. - Vol. 10 (18). - P. 6215-6221.
Harvey H., Lipton A., Lawrence B. et al. Estrogen receptor status in inflammatory breast carcinoma // J. Surg. Oncol. - 1982. - Vol. 21 (1). - P. 42-44.
Kalinsky K., Jacks L., Heguy A. et al. PIK3CA mutation associates with improved outcome in breast cancer // Clin. Cancer Res. - 2009. - Vol. 15. - № 16. - P. 5049-5059.
Lerebours F., CallensC.,Vacher S. Rare overexpression of anaplastic lymphoma kinase gene in inflammatory and non-inflammatory breast cancer // European Journal of Cancer. - 2013. - Vol. 49. - № 12. - P. 2774-2776.
Li S., Rong M., Grieu F. et al. PIK3CA mutations in breast cancer are associated with poor outcome // Breast Cancer Res Treat. - 2006. - Vol. 96. - № 1. - P. 91-95.
Rehman S., Reddy C.A., Tendulkar R.D. Modern Outcomes of Inflammatory Breast Cancer: The Cleveland Clinic Experience // Int. J. Radiat. Oncol. Biol. Phys. -2011. - Vol. 81. - № 2. - P 619-624
Robertson F.M., Bondy M., Yang W. et al. Inflammatory breast cancer: the disease, the biology, the treatment // CA Cancer J. Clin. - 2010. - Vol. 60 ( 6). - Р 351-375.
Robertson F.M., Petricoin Iii E.F., Van Laere S.J. et al. Presence of anaplastic lymphoma kinase in inflammatory breast cancer // Springer Plus. 2013;2:497. doi:10.1186/2193-1801 -2-497.
Samuels Y, Diaz L., Schmidt-Kittler O. et al. Mutant PIK-3CA promotes cell growth and invasion of human cancer cells // Cancer Cell. - 2005. - Vol. 7. - № 6. - P. 561-573.
Thunnissen E., Bubbendorf L., Dietel M. et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations // Virchows Arch. - 2012.- Vol. 461. - № 3. - Р 245-257.
Tsai C., Li J., Gonzalez-Angulo A. et al. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy // Am. J. Clin. Oncol. - 2015. - Vol. 12. - № 17. - Р 223-235.
Tuma R. ALK gene amplified in most inflammatory breast cancers // J Natl Cancer Inst. - 2012. - Vol. 104 (2). -P. 87-88.
Yamauchi H., Woodward W.A., Valero V. et al. Inflammatory breast cancer: what we know and what we need to learn // Oncology. - 2012. - Vol. 17 (7). - P. 891-899.
Wolff A., Hammond E., Hicks D. et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer// Arch Pathol Lab Med. - 2013. - Vol. 31. - № 31. -P. 3997-4013.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...